Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MadeMed vs RxPepsDirect

MadeMed
Graded #30

Higher grade

vs+11.700000000000003
RxPepsDirect
Graded #146

Lower grade

The verdict

MadeMed takes it — 80.4/100 to 68.7/100.

MadeMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Publishes its price at every single dose, so what a titrated dose costs is knowable on day one.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
74
74
Dose & formulationMadeMed +26
90
64
Clinical oversightMadeMed +15
84
69
Labs & monitoringRxPepsDirect +10
62
72
FulfillmentMadeMed +20
90
70
Contract termsMadeMed +33
88
55
MadeMed · left barRxPepsDirect · right bar

The numbers

MetricMadeMedRxPepsDirect
WeighScore80.4/10068.7/100
GradeB−C
Scorecard rank#30#146
Semaglutide$239/mo quarterly (from $199/mo on 6 months)$64/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$399/mo quarterly (from $369/mo on 6 months)$84/mo (starting dose, plus a separate fee, compounded)
Coverage40 states28 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
MadeMed

Graded #30 · B−

Strengths

  • One flat price at every dose, published dose by dose — semaglutide 0.25–2.4mg, tirzepatide 2.5–15mg
  • LegitScript verified, with board-certified physician review and US compounding pharmacies
  • Full refund minus a $39 visit fee if you are not prescribed, stated before checkout
  • Oral semaglutide and oral tirzepatide alongside the injections; free overnight shipping with supplies

Where it loses points

  • The most expensive tirzepatide here at $399/mo quarterly
  • 40 states rather than nationwide
  • No published recurring lab programme
  • Ships one vial every two months, a less flexible cadence than a monthly refill
RxPepsDirect

Graded #146 · C

Strengths

  • Industry-lowest GLP-1 pricing: compounded semaglutide from $25/vial, tirzepatide from $45/vial — no subscription or recurring commitment required
  • Real 503A telehealth Rx: licensed NP/PA prescribers + MD medical director (Dr. Jonathan Snipes, NPI 1821250077); patient-specific Rx dispensed by
  • FedEx overnight shipping at $15 flat; ships pre-reconstituted and includes syringes, alcohol wipes, and reusable cooled travel case
  • Independent batch COA testing by Eagle Analytical (FDA-registered, A2LA ISO 17025): 54/54 sterility and endotoxin passes published publicly on
  • No subscription required; $39 flat visit fee covers up to 3 peptides per Rx; pay per vial with no ongoing commitment

Where it loses points

  • No LegitScript certification; company founded 2026 — no public track record or long-term patient-outcomes data
  • Minimal clinical oversight: $39 asynchronous intake form only — no live video consult required, no labs mandated, no monitoring protocol; lowest
  • Per-vial pricing makes true monthly cost opaque; every refill costs another $39 visit fee on top of vial price and $15 shipping
  • Only 28 states + DC; excludes California, most of the Southeast (AL, AR, GA, MS, NC, SC, TN, VA), and parts of Midwest
  • No coaching, labs, dietitian support, or clinical monitoring included at any tier — purely prescription + dispensing

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard